WHO Preferred Product Characteristics for Malaria Vaccines
Overview
The updated Malaria Vaccine Technology Roadmap outlines the two agreed priority unmet public health needs for malaria vaccine development (represented in the roadmap as two strategic goals). WHO has developed a document entitled Preferred Product Characteristics for Malaria Vaccines. The document provides guidance which vaccine manufacturers and funding agencies can take into account when refining product development plans for their malaria vaccine activities. The document clarifies WHO’s preferences with regard to many criteria that form part of Target Product Profiles, particularly indication, target populations and safety and efficacy data to be generated in clinical trials.
Updated version:
An updated version of this publication is now available as the following: